|We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. For example, here is how to disable FireFox ad content blocking while on Silicon Investor.|
/* 4-01-2011 In @ 0.09 */
By Peter Hristov
Date: Apr 1, 2011
Even though Biomoda, Inc. (OTC:BMOD, BMOD message board) issued the promised update on the pilot study of its CyPath cancer detection method, the company's stock crashed down ruthlessly on a record high volume. The last two days BMOD got trapped in a 50% and 20% decline of the stock value, which wiped out the 280% gain achieved in the last month.
In fact, the last few weeks the company was markedly turning into sorters' favorite with short sales exceeding 50% of the traded volume. Only after the stock value plummeted, did the short selling subside down to 20%.
Even the company's statement that the pilot study of CyPath showed encouraging results couldn't prevent shorters from rejoicing. Its seems that technical analysis and day trading have taken rule over BMOD session these days.
Now that the stock has retracted back to its previous trading channel, the most important question is where will it head next. With short sales having dropped down, it seems that the chances for further depreciation had already been soaked up. However, the company's financial documents show that BMOD is primarily relying on common stock issuance to provide cash and brings forth the looming image of dilution into the stock play.
Therefore, in the coming days the direction of the stock will most likely be under the influence of short-term traders' mood.
|© 2019 Knight Sac Media. Data provided by IEX, Alpha Vantage, Coinbase, Binance, Fintel and CityFALCON News|